Federica Predolini

发表

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2016, Molecular Cancer Therapeutics.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2017, Clinical Cancer Research.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

S. Mane, T. Boggon, Kaya Bilgüvar, 2016, Proceedings of the National Academy of Sciences.

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015, Molecular Cancer Therapeutics.

Dual HER 2 / PIK 3 CA Targeting Overcomes Single-Agent Acquired Resistance in HER 2-Ampli fi ed Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015 .

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Pei Hui, Jonathan Black, David L Rimm, 2016, British Journal of Cancer.

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

N. Rothman, Q. Lan, E. Ratner, 2015, British Journal of Cancer.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

E. Sartori, E. Ratner, D. Silasi, 2017, Gynecologic oncology.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer

Gloria S. Huang, J. Schlessinger, E. Ratner, 2018, Clinical Cancer Research.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

E. Ratner, W. Saltzman, D. Silasi, 2016, Molecular Cancer Therapeutics.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

E. Ratner, D. Silasi, P. Schwartz, 2016, American journal of obstetrics and gynecology.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.